Showing 4501-4510 of 9718 results for "".
- Caliber Imaging & Diagnostics Names Daniel Koon to Director of Global Sales Supporthttps://practicaldermatology.com/news/20140314-caliber_imaging__diagnostics_names_daniel_koon_to_director_of_global_sales_support/2459316/Caliber Imaging & Diagnostics, formerly Lucid, Inc., named Daniel Koon to Director of Global Sales Support, effective immediately. Mr. Koon most recently served as Caliber I.D.'s Research Sales Manager. Mr. Koon has experience in international sales
- MELA Sciences Appoints Dr. Darrell Rigel as Chief Medical Advisor to Its Board of Directorshttps://practicaldermatology.com/news/20131001-mela_sciences_appoints_dr_darrell_rigel_as_chief_medical_advisor_to_its_board_of_directors/2459445/MELA Sciences, Inc., announced that Darrell S. Rigel, MD, MS, Clinical Professor of Dermatology at New York University, Langone Medical Center, has been appointed Chief Medical Advisor to the Company's Board of Directors. Dr. Rigel is a Clinical Profes
- Survey: Scars and Stretch Marks Significantly Impact Women's Confidencehttps://practicaldermatology.com/news/20130318-survey_scarsstretch_marks_have_significant_negative_impact_womens_confidence/2459586/A new survey reveals that men and women have complex and often differing feelings about how their skin Imperfections impact their appearance and confidence. In the Mederma® Wear Your Skin Proudly™ survey, 34 percent of women reported that the appearance of scar(s) and/or stretch marks would make the
- Tana Poppino to Be Celtic Complexion Sponsorhttps://practicaldermatology.com/news/20130110-tana_poppino_to_be_celtic_complexion_sponsor/2459641/Florida-based skin care company Celtic Complexion announced a sponsorship agreement with professional rodeo barrel racer Tana Poppino. Ms. Poppino, who lives in Big Cabin, OK, is a full-time contestant on the professional rodeo circuit. S
- Skin Tightening Induced by Fractional CO2 Laserhttps://practicaldermatology.com/news/20120918-skin_tightening_induced_by_fractional_co2_laser/2459735/Variations in mechanical properties of treated skin confirm skin tightening after CO2 fractional resurfacing laser treatment. (J Cosmet Dermatol; 11(3):201-6) Researchers measured dermal elasticity using suction applied with an in vivo skin elasticity meter (Cutometer). Significant improvement was s
- New School Initiative for Skin Cancer Preventionhttps://practicaldermatology.com/news/20120515-new_school_initiative_for_skin_cancer_prevention/2459798/La Roche-Posay recently collaborated with the Women's Dermatologic Society to launch “Time Out, Protect Your Skin” (TOPS) in schools to educate children and families about skin cancer prevention. New York City's Grace Church School was the first s
- Delicious Living magazine recognizes Wildly Natural Seaweed Body Creamhttps://practicaldermatology.com/news/20120229-delicious_living_magazine_recognizes_wildly_natural_seaweed_body_cream/2459862/The Delicious Living 2012 Beauty & Body Award for “Best New Product” went to The Seaweed Bath Co.'s Wildly Natural SeaweedTM Body Cream, the company announced. Delicious Living chose winners based on the products' efficacy without sacrificing purity, innovation and their dedication to raising standa
- Early Data Presented for Celotres™ for Keloid Scarshttps://practicaldermatology.com/news/20120224-early_data_presented_for_celotres_for_keloid_scars/2459866/Results from Halscion, Inc.'s KLEAR Study, which evaluated the initial safety and efficacy of Celotres™ in the treatment of keloid scars adjunctive to surgical excision, show a significant reduction (p=0.0110) in keloid recurrence, as compared to scientific literature, following a single treatment o
- Better Together: Castle Biosciences’ Full DecisionDx Portfolio to Be Interfaced with ModMed’s EMAhttps://practicaldermatology.com/news/better-together-castle-biosciences-full-decisiondx-portfolio-to-be-interfaced-with-modmeds-ema/2460982/Castle Biosciences, Inc’s full DecisionDx portfolio of dermatologic tests will be interfaces with EMA, ModMed’s electronic health records system, by year-end 2021 The interface is designed to enable dermatologic clinicians to order Castle’s De
- DecisionDx-Melanoma Accurately Predicts Patient Outcomes in Cutaneous Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-accurately-predicts-patient-outcomes-in-cutaneous-melanoma/2460746/Castle Biosciences, Inc.’s DecisionDx-Melanoma is a significant, independent predictor of patient outcomes in cutaneous melanoma. DecisionDx-Melanoma is Castle’s gene expression profile test that uses an individual patient’s tumor biology to predict risk of cutane